What we do
Overcoming the Limitations of PROTACs and Cereblon.
Plexium's best-in-class platform propels us toward the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unravelling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. There's a vast undruggable universe to be explored, and we're just getting started.Our team